These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10053209)

  • 1. Transdermal delivery of naloxone: ex vivo permeation studies.
    Jaiswal J; Poduri R; Panchagnula R
    Int J Pharm; 1999 Mar; 179(1):129-34. PubMed ID: 10053209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin.
    Panchagnula R; Salve PS; Thomas NS; Jain AK; Ramarao P
    Int J Pharm; 2001 May; 219(1-2):95-105. PubMed ID: 11337170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist.
    Yamamoto R; Takasuga S; Yoshida Y; Mafune S; Kominami K; Sutoh C; Kato Y; Yamauchi M; Ito M; Kanamura K; Kinoshita M
    Int J Pharm; 2012 Jan; 422(1-2):132-8. PubMed ID: 22108639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of ethosomes and chemical enhancers on enhancement of naloxone permeation through human skin.
    Xu DH; Zhang Q; Feng X; Xu X; Liang WQ
    Pharmazie; 2007 Apr; 62(4):316-8. PubMed ID: 17484292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is transdermal iontophoretic delivery of naloxone sufficient for the management of intoxication in opioid-overdosed patients?
    Sanaei-Zadeh H
    Int J Pharm; 2012 May; 428(1-2):187. PubMed ID: 22426321
    [No Abstract]   [Full Text] [Related]  

  • 6. Iontophoresis-coupled rapidly dissolving polymeric microneedle patch of naloxone for its enhanced transdermal delivery.
    Tijani AO; Connors D; Schiavone C; Peláez MJ; Dogra P; Puri A
    Int J Pharm; 2024 Jul; 660():124289. PubMed ID: 38825171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies.
    Panchagnula R; Bokalial R; Sharma P; Khandavilli S
    Int J Pharm; 2005 Apr; 293(1-2):213-23. PubMed ID: 15778059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro permeation of carvedilol through porcine skin: effect of vehicles and penetration enhancers.
    Gannu R; Vishnu YV; Kishan V; Rao YM
    PDA J Pharm Sci Technol; 2008; 62(4):256-63. PubMed ID: 19174954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study for transdermal delivery of meperidine.
    Ritschel WA; Barkhaus JK
    Methods Find Exp Clin Pharmacol; 1988 Jul; 10(7):461-5. PubMed ID: 3419250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Hydrogels for Microneedle-Assisted Transdermal Delivery of Naloxone for Opioid-Induced Pruritus.
    Gao X; Brogden NK
    J Pharm Sci; 2019 Nov; 108(11):3695-3703. PubMed ID: 31476312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis.
    Krishnaiah YS; Satyanarayana V; Karthikeyan RS
    J Pharm Pharm Sci; 2002; 5(2):123-30. PubMed ID: 12207864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of skin hydration and its barrier function by vehicle and permeation enhancers: a study using TGA, FTIR, TEWL and drug permeation as markers.
    Shah DK; Khandavilli S; Panchagnula R
    Methods Find Exp Clin Pharmacol; 2008 Sep; 30(7):499-512. PubMed ID: 18985178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
    Aboofazeli R; Zia H; Needham TE
    Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
    Milewski M; Stinchcomb AL
    Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
    Milewski M; Pinninti RR; Stinchcomb AL
    J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.
    Kanaan M; Daali Y; Dayer P; Desmeules J
    Fundam Clin Pharmacol; 2009 Oct; 23(5):543-8. PubMed ID: 19656202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations.
    Funke AP; Schiller R; Motzkus HW; Günther C; Müller RH; Lipp R
    Pharm Res; 2002 May; 19(5):661-8. PubMed ID: 12069170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of an influx transporter in the blood-brain barrier transport of naloxone.
    Suzuki T; Ohmuro A; Miyata M; Furuishi T; Hidaka S; Kugawa F; Fukami T; Tomono K
    Biopharm Drug Dispos; 2010 May; 31(4):243-52. PubMed ID: 20437463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal delivery of buprenorphine through cadaver skin.
    Roy SD; Roos E; Sharma K
    J Pharm Sci; 1994 Feb; 83(2):126-30. PubMed ID: 8169777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics.
    Tirunagari M; Jangala VR; Khagga M; Gannu R
    Arch Pharm Res; 2010 Jul; 33(7):1025-33. PubMed ID: 20661712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.